Ladenburg Thalmann

Peraso Inc. Announces Exercise of Warrants for $2.9 Million in Gross Proceeds For more info: https://lnkd.in/eF_Pn7qy

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock For more info: https://lnkd.in/e7aQ4CX9

Nuwellis, Inc. Announces Exercise of Warrants for $3.8 Million of Gross Proceeds For more info: https://lnkd.in/ewi4i7d8

Catheter Precision, Inc. Announces Exercise of Warrants for $3.7 Million of Gross Proceeds For more info: https://lnkd.in/ePC3SNeQ

Ladenburg Thalmann & Co. is pleased to announce the Virtual Oncology Innovators & Investors Symposium, scheduled for December 12, 2024. This event will bring together innovators and investors to discuss advancements in cancer treatment and new investment opportunities in biotechnology. Event Highlights: -Presentations on leading oncology technologies and treatments -Q&A sessions with Ladenburg biotechnology analysts Aydin Huseynov, M.D., CFA and Matt Kaplan -One-on-one virtual meetings Date: December 12, 2024 Location: Virtual For registration details, please visit https://lnkd.in/eGEcYDRF or contact your Ladenburg Institutional Representative.?

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement For more info: https://lnkd.in/gt-jiHhr

I'm excited to engage with our Osaic Financial Professionals at #ConnectEd24 in Orlando! I will be leading two high-net-worth focused breakout sessions. I hope to see you on Monday at 2:40 p.m. in the "Winning High-Net-Worth Opportunities" session, and again on Tuesday at 12:30 p.m. in a follow-on session with Oxford Funds, “Enhancing Portfolios for Endowments and HNW Clients - The Case for CLO Equity.”

Ladenburg Thalmann Welcomes Murat Omur as Managing Director in Healthcare Investment Banking New York, NY, October 14, 2024 — Ladenburg Thalmann, a leading firm in the investment banking industry, is excited to announce the appointment of Murat Omur as Managing Director in the Healthcare Investment Banking division. Murat Omur has 17 years of investment banking experience in healthcare and M&A space. Prior to joining Ladenburg, Mr. Omur was a Managing Director in Healthcare Investment Banking at Chardan, working on capital markets and M&A transactions in biotech and CDMO space. Before Chardan, he worked at Nomura Securities, Perella Weinberg Partners and Merrill Lynch, working on M&A transactions with a focus on life sciences space. Mr. Omur holds a BA from Bosphorus University, MA from Johns Hopkins University, and MBA from Columbia Business School. “We are excited to have Murat Omur on board. His deep industry knowledge and leadership will be invaluable as we continue to grow and strengthen our presence in healthcare investment banking” said Nicholas Stergis, Head of Investment Banking at Ladenburg Thalmann.

Legacy Education, Inc. Announces Closing of $11.5 Million Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option For more info: https://lnkd.in/evwzcUHf

I had the pleasure of sharing insights on the latest trends in healthcare technologies and capital markets during the Introductory Keynote Presentation at the 11th Annual HealthTech Investment Forum (#Sachs_HTIF) on September 24, 2024, in Basel. It was a great opportunity to see so many innovative ideas and companies showcased and engage with industry leaders in Digital Health and MedTech